Left ventricular remodeling in patients with ankylosing spondylitis
Year: 2020, volume 16 Issue: №3 Pages: 743-747
Heading: Cardiology Article type: Original article
Authors: Makhina V.I, Rebrov А.Р.
Organization: Saratov State Medical University
Heading: Cardiology Article type: Original article
Authors: Makhina V.I, Rebrov А.Р.
Organization: Saratov State Medical University
Summary:
The goal is to study the features of heart remodeling in patients with ankylosing spondylitis (AS) who do not have cardiovascular diseases. Material and Methods: The study included 90 patients (aged 18 and older) with AS. The assessment of disease activity was determined using BASDAI (Bath AS Disease Activity Index) and ASDAS (The Anky- losing Spondylitis Disease Activity Score) indices. All patients underwent transthoracic echocardiography (EchoCG) was performed to assess the state of the heart. Depending on the values of the left ventricular (LV) mass index and the relative LV wall thickness index, various types of LV hypertrophy and remodeling were identified. Results: The median age of patients was 38 [33; 46], the average duration of AS was 15.7±7.3 years; 61 of the patients (68%) were male. According to the echocardiographic study, 72 (80%) patients showed normal LV geometry and 18 (20%) showed signs of LV myocardium remodeling. Concentric remodeling of the left ventricular myocardium was observed for 9 (50%) patients, concentric hypertrophy was observed in 4 cases (22.2%), eccentric hypertrophy — in 5 cases (27.8%). Conclusion: Structural and functional changes of the heart were detected in 20% of young patients with AS without a history of cardiovascular diseases. EchoCG can serve as a method of early diagnosis of cardiovascular system pathology in young patients with ankylosing spondylitis who do not have cardiovascular diseases.
Keywords: ankylosing spondylitis
Bibliography:
1. Rheumatology. Clinical guidelines / Ed. by Nason-ov E. L. Moscow: GEOTARMedia; 2010; p. 58-77.
2. Rebrov АР, Gaidukova IZ, Poddubnyy DA. Cardiovascular pathology in patients with ankylosing spondylitis. Rheumatology Science and Practice. 2012; (2): 100-5.
3. Heslinga SC, Van den Oever IA, Van Sijl AM, et al. Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. ВМС Musculoskelet Disord2015; (16): 80.
4. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, mincluding ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014; 73 (1): 6-16.
5. Bartoloni E, Alunno A, Valentini V, et al. Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality? Front Cardiovasc Med 2018; (5): 177.
6. Ozkan Y. Cardiac Involvement in Ankylosing Spondylitis. Clin Med Res 2016; 8 (6): 427-30.
7. Lonnebakken MT, Raffaele I, Costantino M, et al. Left ventricular hypertrophy regression during antihypertensive treatment in an outpatient clinic (the Campania Salute Network). J Am Heart Assoc 2017; 6 (3): e004152. DOI: 10.1161/JAHA. 116.004152.
8. Leonardo S, Maurizio F, Silvia P, et al. A review of the molecular mechanisms underlying the development and progression of cardiac remodeling. Oxid Med Cell Longev 2017; (2017): 3920195.
9. Nigmatzyanova A, Mangusheva M, Lapshina S. Electro physiological Cardiac Remodeling in Patients with Ankylosing Spondylitis. Annals of the Rheumatic Diseases 2016; 75 (Suppl2):581-3.
| Attachment | Size |
|---|---|
| 2020_03_743-747.pdf | 307.25 KB |
Русский
English